KeyNeurotek Pharmaceuticals is focused on drug development for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s portfolio covers the entire drug development chain from research stage to advanced clinical development. The lead candidates KN38-7271 and KN203, addressing significant markets such as traumatic brain injury (TBI), stroke, and urinary incontinence/overactive bladder, are in Phase II clinical development. KeyNeurotek’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system (TELOMICS™). The company is located in Magdeburg, Germany – one of the leading European research centers in neuroscience.

Speaker Profile

Dr. Frank Striggow, CEO

Dr. Frank Striggow is CEO and co-founder of KeyNeurotek Pharmaceuticals. He held group leader positions at Institute of Neurobiochemistry, Otto-von-Guericke University Magdeburg and Julius-Bernstein-Institute of Physiology, Martin Luther-University Halle/Wittenberg, Germany. Previously, he was postdoctoral fellow of the American Heart Association and the German Academic Exchange service at UCONN Health Centre, Farmington, CT and MBL, Woods Hole, MA, USA. Dr. Striggow holds a PhD in biochemistry.